U.S. markets closed

Compugen Ltd. (CGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.38-0.60 (-4.29%)
At close: 4:00PM EDT

13.38 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close13.98
Open13.59
Bid13.31 x 1000
Ask14.09 x 800
Day's Range13.27 - 13.75
52 Week Range4.49 - 19.90
Volume508,121
Avg. Volume1,481,235
Market Cap1.12B
Beta (5Y Monthly)2.75
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?
    Zacks

    What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?

    On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.

  • Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy
    PR Newswire

    Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy

    Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of new research data further supporting PVRIG as a potentially promising target for cancer immunotherapy. These data suggest that PVRIG inhibition may enhance T cell priming and infiltration into tumors and provide further evidence supporting the potential advantages of targeting PVRIG alone and in combination with TIGIT and PD-1 inhibitors, in tumors for which current checkpoint blockers have not proven successful. The new findings are delivered in a presentation at the 2020 TIGIT Therapies Digital Summit today, October 27, 2020, at 11:00 AM EDT.

  • Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?
    Zacks

    Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?

    On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.